170 related articles for article (PubMed ID: 17640442)
21. The association between suicidality and treatment with selective serotonin reuptake inhibitors in older people with major depression: a systematic review.
KoKoAung E; Cavenett S; McArthur A; Aromataris E
JBI Database System Rev Implement Rep; 2015 Apr; 13(3):174-205. PubMed ID: 26447056
[TBL] [Abstract][Full Text] [Related]
22. Suicidal risk during controlled clinical investigations of fluvoxamine.
Letizia C; Kapik B; Flanders WD
J Clin Psychiatry; 1996 Sep; 57(9):415-21. PubMed ID: 9746450
[TBL] [Abstract][Full Text] [Related]
23. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
Acharya N; Rosen AS; Polzer JP; D'Souza DN; Perahia DG; Cavazzoni PA; Baldessarini RJ
J Clin Psychopharmacol; 2006 Dec; 26(6):587-94. PubMed ID: 17110815
[TBL] [Abstract][Full Text] [Related]
24. Suicidality with selective serotonin reuptake inhibitors: Valid claim?
Lapierre YD
J Psychiatry Neurosci; 2003 Sep; 28(5):340-7. PubMed ID: 14517577
[TBL] [Abstract][Full Text] [Related]
25. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
Hetrick S; Merry S; McKenzie J; Sindahl P; Proctor M
Cochrane Database Syst Rev; 2007 Jul; (3):CD004851. PubMed ID: 17636776
[TBL] [Abstract][Full Text] [Related]
26. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode.
Seemüller F; Riedel M; Obermeier M; Bauer M; Adli M; Mundt C; Holsboer F; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Jäger M; Henkel V; Möller HJ
Int J Neuropsychopharmacol; 2009 Mar; 12(2):181-9. PubMed ID: 18662490
[TBL] [Abstract][Full Text] [Related]
27. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.
Stone M; Laughren T; Jones ML; Levenson M; Holland PC; Hughes A; Hammad TA; Temple R; Rochester G
BMJ; 2009 Aug; 339():b2880. PubMed ID: 19671933
[TBL] [Abstract][Full Text] [Related]
28. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
[TBL] [Abstract][Full Text] [Related]
29. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects.
Leon AC; Keller MB; Warshaw MG; Mueller TI; Solomon DA; Coryell W; Endicott J
Am J Psychiatry; 1999 Feb; 156(2):195-201. PubMed ID: 9989554
[TBL] [Abstract][Full Text] [Related]
30. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
31. [Fluoxetine, akathisia and suicide].
Lançon C; Bernard D; Bougerol T
Encephale; 1997; 23(3):218-23. PubMed ID: 9333553
[TBL] [Abstract][Full Text] [Related]
32. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
[TBL] [Abstract][Full Text] [Related]
33. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study.
Maund E; Tendal B; Hróbjartsson A; Lundh A; Gøtzsche PC
BMJ; 2014 Jun; 348():g3555. PubMed ID: 24899651
[TBL] [Abstract][Full Text] [Related]
34. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports.
Sharma T; Guski LS; Freund N; Gøtzsche PC
BMJ; 2016 Jan; 352():i65. PubMed ID: 26819231
[TBL] [Abstract][Full Text] [Related]
35. [SSRIs (selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children].
Tandt H; Audenaert K; van Heeringen C
Tijdschr Psychiatr; 2009; 51(6):387-93. PubMed ID: 19517368
[TBL] [Abstract][Full Text] [Related]
36. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
Tourian KA; Padmanabhan K; Groark J; Ninan PT
J Clin Psychopharmacol; 2010 Aug; 30(4):411-6. PubMed ID: 20631558
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological treatment of children and adolescents with depression.
Vitiello B; Ordóñez AE
Expert Opin Pharmacother; 2016 Dec; 17(17):2273-2279. PubMed ID: 27690663
[TBL] [Abstract][Full Text] [Related]
38. Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: an update.
Giner L; Nichols CM; Zalsman G; Oquendo MA
Int J Adolesc Med Health; 2005; 17(3):211-20. PubMed ID: 16231472
[TBL] [Abstract][Full Text] [Related]
39. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries.
Rihmer Z; Akiskal H
J Affect Disord; 2006 Aug; 94(1-3):3-13. PubMed ID: 16712945
[TBL] [Abstract][Full Text] [Related]
40. Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.
Meyer RE; Salzman C; Youngstrom EA; Clayton PJ; Goodwin FK; Mann JJ; Alphs LD; Broich K; Goodman WK; Greden JF; Meltzer HY; Normand SL; Posner K; Shaffer D; Oquendo MA; Stanley B; Trivedi MH; Turecki G; Beasley CM; Beautrais AL; Bridge JA; Brown GK; Revicki DA; Ryan ND; Sheehan DV
J Clin Psychiatry; 2010 Aug; 71(8):e1-e21. PubMed ID: 20797373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
